Cue Biopharma Inc (CUE)
1.02
-0.01
(-0.97%)
USD |
NASDAQ |
Nov 22, 16:00
1.05
+0.03
(+2.94%)
After-Hours: 20:00
Cue Biopharma Cash from Operations (Quarterly): -7.527M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -7.527M |
| June 30, 2024 | -9.99M |
| March 31, 2024 | -9.784M |
| December 31, 2023 | -10.96M |
| September 30, 2023 | -7.799M |
| June 30, 2023 | -10.37M |
| March 31, 2023 | -10.83M |
| December 31, 2022 | -10.51M |
| September 30, 2022 | -6.871M |
| June 30, 2022 | -12.85M |
| March 31, 2022 | -11.57M |
| December 31, 2021 | -10.65M |
| September 30, 2021 | -6.627M |
| June 30, 2021 | -9.77M |
| March 31, 2021 | -11.80M |
| December 31, 2020 | -6.999M |
| Date | Value |
|---|---|
| September 30, 2020 | -7.687M |
| June 30, 2020 | -6.864M |
| March 31, 2020 | -10.94M |
| December 31, 2019 | -6.438M |
| September 30, 2019 | -9.208M |
| June 30, 2019 | -6.676M |
| March 31, 2019 | -8.475M |
| December 31, 2018 | -3.898M |
| September 30, 2018 | -6.298M |
| June 30, 2018 | -6.456M |
| March 31, 2018 | -9.759M |
| December 31, 2017 | -1.845M |
| September 30, 2017 | -3.676M |
| June 30, 2017 | -3.156M |
| March 31, 2017 | -3.464M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-12.85M
Minimum
Jun 2022
-6.438M
Maximum
Dec 2019
-9.342M
Average
-9.887M
Median
Cash from Operations (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 221.48M |
| Arbutus Biopharma Corp | -20.74M |
| GlycoMimetics Inc | -7.994M |
| FibroGen Inc | -8.376M |
| Cidara Therapeutics Inc | -36.70M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 0.098M |
| Cash from Financing (Quarterly) | 9.821M |
| Free Cash Flow | -38.32M |
| Free Cash Flow Per Share (Quarterly) | -0.1469 |
| Free Cash Flow to Equity (Quarterly) | -6.568M |
| Free Cash Flow Yield | -75.88% |